[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AdventHealth Translational Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":255},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,71,94,120,143,166,188,208,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325",false,"NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[26,27,28,29,30,31],"Gastric Cancer (Diagnosis)","Esophagus Cancer","Pancreas Cancer","Colon Cancer","Rectal Cancer","Lung Cancer","NOT_YET_RECRUITING","2026-05-13",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":20},"2026-07-01",{"date":40,"type":20},"2027-12-31",{"name":42,"class":43},"AdventHealth Translational Research Institute","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100592440","acute-exercise-and-endogenous-glucose-production-in-type-2-diabetes-implications-for-glycemic-control-and-treatment-of-hepatic-steatosis-100592440","NCT06993454","Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis","ACELERATE-P","Inclusion criteria for individuals with T2D and elevated liver fat ≥5.6%\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or (pre-menopausal) female, aged 25-55 years\n4. Body mass index (BMI) between 25 and 45 kg\u002Fm2\n5. Sedentary (1 day or less per week of structured exercise)\n6. Type 2 diabetes mellitus: HbA1c ≥7.5%\n7. Liver fat ≥5.6% based on MRI\n8. Weight stable (± 2 kg) for prior 3 months\n\nInclusion criteria for lean, healthy controls\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or (pre-menopausal) female, aged 25-55 years\n4. Body mass index (BMI) between 18.5 and 27.5 kg\u002Fm2\n5. Normal liver fat (FibroScan CAP \\\u003C249dB\u002Fm, \\\u003C5.6% liver fat based on MRI)\n6. Weight stable (± 2 kg) for prior 3 months\n7. Active (≥3 day\u002Fweek of structured exercise)\n\nExclusion Criteria\n\n1. Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and\u002For thiazolidinediones\n2. Any change in glucose-lowering medications within the previous three months.\n3. Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7.\n4. Resting blood pressure ≥ 160\u002F100 mm Hg\n5. Triglycerides ≥ 500 mg\u002FdL\n6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol\n7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)\n8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing\n9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)\n10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months\n11. Post- or peri-menopausal women\n12. Partial and\u002For full hysterectomy (self-report)\n13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc\n14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting\n15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures\n16. New onset (\\\u003C3 months on a stable regime) hormone replacement therapy\n17. Current use of beta-adrenergic blocking agents\n18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months\n19. Previous bariatric or other surgery for obesity\n20. Abnormal blood count\u002Fanemia (hemoglobin \\\u003C12 g\u002Fdl in men or 11 g\u002Fdl in women; Hct \\\u003C34%), blood transfusion or blood donation within the last 2 months\n21. Current smokers (smoking within the past 3 months prior to screening visit, including any\u002Fall tobacco products)\n22. Current drug or alcohol abuse\u002Fdependence, or positive urine toxicology screen\n23. Alcohol consumption \\>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)\n24. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening\n25. Not physically capable of performing the exercise required of the study protocols\n26. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.\n27. Unable to tolerate MRI or claustrophobia.\n28. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year\n29. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy\n30. Unable or unwilling to communicate with staff or to provide written informed consent\n\nExclusion criteria for lean, healthy controls\n\n1. Currently taking insulin, injectable incretin mimetics, and\u002For thiazolidinediones\n2. Taking glucose-lowering medications\n3. HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes\n4. Resting blood pressure ≥ 160\u002F100 mm Hg\n5. Triglycerides ≥ 500 mg\u002FdL\n6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol\n7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)\n8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing\n9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)\n10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year\n11. Post- or peri-menopausal women\n12. Partial and\u002For full hysterectomy (self-report)\n13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc\n14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting\n15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures\n16. New onset (\\\u003C3 months on a stable regime) hormone replacement therapy\n17. Current use of beta-adrenergic blocking agents\n18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months\n19. Previous bariatric or other surgery for obesity\n20. Increased liver function tests (AST\u002FALT\u002FGGT\u002For alkaline phosphatase greater than 2.5 times the upper limit of normal)\n21. Abnormal blood count\u002Fanemia (hemoglobin \\\u003C12 g\u002Fdl in men or 11 g\u002Fdl in women; Hct \\\u003C34%), blood transfusion or blood donation within the last 2 months\n22. Current smokers (smoking within the past 3 months prior to screening visit, including any\u002Fall tobacco products)\n23. Current drug or alcohol abuse\u002Fdependence, or positive urine toxicology screen\n24. Alcohol consumption \\>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)\n25. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening\n26. Not physically capable of performing the exercise required of the study protocols\n27. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.\n28. Unable to tolerate MRI or claustrophobia.\n29. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year\n30. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy\n31. Unable or unwilling to communicate with staff or to provide written informed consent",true,"25 Years","55 Years",{"count":55,"type":20},12,[23],"The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).",[59,60],"Type 2 Diabetes","Hepatic Steatosis","RECRUITING","2026-04-15",{"date":64,"type":36},"2026-04-17",{"date":66,"type":36},"2025-04-25",{"date":68,"type":20},"2026-04",{"name":42,"class":43},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":51,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":70},"100632655","determining-cell--and-spatially-distinct-skeletal-muscle-transcriptional-aberrations-in-insulin-resistance-100632655","NCT07516509","Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance","Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations With Insulin Resistance","POINTS 2","Inclusion Criteria:\n\n* All Groups\n\n  1. 30 to 65 years of age\n  2. Stable weight (No Gain\u002FLoss of \\>10 lbs in 6 months)\n  3. Sedentary (≤ 1 continuous exercise\u002Fweek)\n  4. Non-smoker\n  5. Resting Blood Pressure ≤ 150mmHg systolic and ≤ 95 mmHg diastolic\n\nGroup A - Lean individuals with insulin sensitivity (IS-Lean)\n\n1. BMI 18-25 kg\u002Fm2\n2. Hemoglobin A1c ≤ 5.6% at screening\n3. Blood glucose level ≤ 140 mg\u002FdL 2hr after a 75g oral glucose tolerance test\n\nGroup B - Individuals with obesity and insulin sensitivity (IS-Obesity)\n\n1. BMI 30-40 kg\u002Fm2\n2. Hemoglobin A1c ≤ 5.6% at screening\n3. Blood glucose level ≤ 140 mg\u002FdL 2hr after a 75g oral glucose tolerance test\n\nGroup C - Individuals with obesity and insulin resistance (IR-Obesity)\n\n1. BMI 30-40 kg\u002Fm2\n2. Hemoglobin A1c ≤ 6.4 % at screening\n3. Blood glucose level 140-199 mg\u002FdL 2hr after a 75g oral glucose tolerance test\n\nExclusion Criteria:\n\n1. Clinically significant CVD including h\u002Fo MI, within the past year\n2. Peripheral Vascular Disease\n3. Diagnosed with Type I or Type II diabetes\n4. Hepatic, renal, muscular\u002Fneuromuscular, or active hematologic\u002Foncologic disease\n5. Previous history of pulmonary emboli\n6. Peripheral Neuropathy\n7. Anemia (Hematocrit \\\u003C34%, Hemoglobin \\\u003C 14 gm\u002FdL for men and \\\u003C12.3 gm\u002FdL for women) at screening\n8. Currently pregnant (pregnancy test performed on day of DEXA scan in women of child-bearing potential); post-partum during the last 12 months; lactating during the last 12 months; planning to become pregnant during the participation period\n9. Polycystic Ovarian Syndrome (PCOS) (self-report)\n10. Hospitalization for COVID-19 infection in the past 12 months; individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days\n11. Partial and\u002For full hysterectomy (self-report)\n12. Not willing to archive biospecimens for future use\n13. Any contraindications to exercise testing according to ACSM guidelines\n14. Inability and\u002F or unwillingness to comply with the protocol as written\n15. Active alcohol or substance abuse (Past 5 Years)\n16. Positive toxicology result from screening visit or chronic use of Amphetamine, Barbiturate, Benzodiazepine, Cocaine, Methadone, Opiate, THC, Cannabis, Tricyclics, or Oxycodone.\n17. Dyslipidemia (fasting triglycerides \\>500 mg\u002FdL; low-density lipoprotein cholesterol (LDL-C) \\>190 mg\u002FdL; total cholesterol \\>300 mg\u002FdL);\n18. ALT \\>80, AST\\>80, Alk Phos \\>240 if a participant presents with liver functions out of these ranges at screening the MI or PI can give discretion to participate\n19. Proteinuria (defined as \\> 1+) at screening\n20. Kidney disease (creatinine \\>1.6 mg\u002Fdl or estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m2);\n21. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy.\n22. Receiving active treatment (including monoclonal antibodies) for autoimmune disorders within the last 6 months;\n23. Hypothyroidism (sTSH\\>8) at screening or on thyroid replacement therapy\n24. Abnormal bleeding or coagulopathy (self-report) or history of a bleeding disorder or clotting abnormality\n25. History of cancer (other than non-melanoma skin cancer) within the last 5 years (not in remission); anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months;\n26. Previous bariatric or other surgery for obesity\n27. Females currently on hormone replacement therapy (HRT) less than 6 months\n28. Females with an irregular menstrual cycle\n29. Previous difficulty with lidocaine or other local anesthetic\n30. ACS symptoms:\n\n    * Positive ECG (\\> 2mm ST segment depression) without PCP cardiologist permission to participate\n    * Signs or symptoms of cardiovascular decomposition (eg. hypotensive response to exercise)\n    * Onset of angina or angina like symptoms, shortness of breath, change in heart rhythm, signs of poor perfusion (light-headedness), tightness.\n31. The following medication use is exclusionary;\n\n    * Dose change for any chronic-use drug in the last 3 months;\n    * Any medications that can alter glucose homeostasis (eg. steroids, glucocorticoids, nicotinic acid). Acute therapy (5-7 days) is not exclusionary however; participant must be agreeable to a washout period of 5-7 days prior to day of biopsy.\n    * Blood thinners such as Coumadin, Lovenox etc. Aspirin is not exclusionary however; participant must be agreeable to a washout period of \\> 10 days prior to day of biopsy\n    * All Weight loss medications including but not limited toGLP-1 agonists- Wegovy, liraglutide, semaglutide, Trulicity (dulaglutide), Phentermine and Contrave\n    * Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg\u002Fday);\n    * Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit\u002FHyperactivity Disorder (ADHD) drugs, anti-psychotic drugs, anti-depressant medication (e.g. Bupropion, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine re-uptake inhibitors (SNRIs)).\n    * Pulmonary\u002FInflammation: chronic oral steroids (occasional use of inhaled steroids are allowed), burst\u002Ftaper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months).\n    * Genitourinary: 5-alpha reductase inhibitors, daily use of phosphodiesterase type 5 inhibitor.\n    * Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and\u002For progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone,\n    * any drugs used to treat diabetes mellitus or lower blood glucose including metformin, thiazolidinediones, SGLT-2 inhibits or insulin\n    * any drugs used specifically to induce muscle growth\u002Fhypertrophy or augment exercise-induced muscle hypertrophy\n    * Pain\u002FInflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week\n    * Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous\u002Fchronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications\u002Fimmune suppressants. Participants can be re-screened after a 3 month washout period if antimicrobial use is only used acutely \\\u003C 2 weeks.\n32. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.","30 Years","65 Years",{"count":82,"type":20},36,"OBSERVATIONAL","The purpose of this study is to find new signs or signals in muscle cells that can help us understand when the body isn't responding well to insulin (a condition called insulin resistance).",[86],"Insulin Resistance","2026-04-10",{"date":62,"type":36},{"date":90,"type":20},"2026-06",{"date":92,"type":20},"2028-12",{"name":42,"class":43},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":51,"sex":16,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100259973","development-and-validation-of-multi-nuclear-magnetic-resonance-imaging-and-spectroscopy-for-whole-body-human-applications-100259973","NCT02663362","Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications","MRS VALIDATION","Inclusion Criteria:\n\n* Male or female\n* Age 12 - 89\n* Healthy (self assessed)\n* Weight under 350lbs\n* Able to walk 50 yards without stopping\n* Able to travel to hospital for study visits\n* Able to follow a 3-step command\n* Able to remain in Magnetic Resonance (MR) scanner for up to 2 hours\n\nExclusion Criteria:\n\n* Have internal metal medical devices, including cardiac pacemakers, aortic or cerebral aneurysm clips, artificial heart valves, ferromagnetic implants, shrapnel, wire sutures, joint replacements, bone or joint pins\u002Frods\u002Fscrews, metal fragments in your eye, or non-removable jewelry such as rings.\n* Are unwilling or unable to complete the imaging procedures for the duration of the MRI scan due to claustrophobia or other reason.\n* Serious mental illness that might preclude subject's ability to comply with study treatment\n* Life expectancy of less than 1 year\n* Are pregnant or plan on becoming pregnant in the next 8 weeks.","12 Years","89 Years",{"count":104,"type":20},250,"The purpose of this study is to develop and refine the techniques for using magnetic resonance imaging and magnetic resonance spectroscopy to understand the composition and function of the human body",[107,108],"Human Body Composition","Human Body Function",[110,111],"magnetic resonance imaging","magnetic resonance spectroscopy","2026-03-25",{"date":114,"type":36},"2026-03-30",{"date":116,"type":4},"2012-02",{"date":118,"type":20},"2027-01",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100562359","assessments-of-adipogenesis-lipid-turnover-and-cellular-composition-in-adipose-tissue-in-response-to-endurance-exercise-100562359","NCT06602141","Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise","ATLAS","Inclusion Criteria:\n\n1. Men and pre-menopausal women;\n2. 18-45 years of age;\n3. BMI 30.0-40.0 kg\u002Fm2;\n4. For women, if not using pharmaceutical (hormonal) contraception (i.e. birth control pills, vaginal ring, injections, or implant), must agree to use either a double barrier method as a form of birth control to prevent pregnancy (i.e. male condom with spermicide, with or without cervical cap or diaphragm); use implants or intrauterine contraceptive devices; have a tubal ligation (surgically sterile); practice abstinence; or be in an established relationship with a vasectomized or same sex partner during the entire duration of the study;\n5. Able to speak and understand written and spoken English;\n6. Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) endurance or resistance exercise in the past year.\n7. Must be willing to be randomized to either study group;\n8. Must be willing to adhere to all study procedures.\n9. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board\u002FIndependent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.\n\nExclusion Criteria:\n\n1. Self-reported unstable body weight in the last 3 months (\\> ±5%);\n2. Significant changes in the quality of the diet or the level of physical activity within the last 3 months;\n3. Weight \\>396 lb (180 kg);\n4. Diagnosis of Type 1 or Type 2 diabetes mellitus;\n5. Fasting blood glucose ≥126 mg\u002FdL;\n6. HbA1c ≥ 6.5%\n7. Blood pressure \\>140\u002F90 mmHg ;\n8. Self-reported history or presence of the following cardiovascular conditions: congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, symptomatic peripheral artery disease, stable angina, myocardial infarction or coronary revascularization within 6 months; clinically significant abnormalities on ECG, presence of cardiac pacemaker, or implanted cardiac defibrillator; inability to complete the VO2max test;\n9. Anemia (hemoglobin \\\u003C12 g\u002Fdl in men or 11 g\u002Fdl in women; Hct \\\u003C34%);\n10. Kidney disease (creatinine \\>1.6 mg\u002Fdl or estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m2);\n11. Abnormal liver enzymes (\\>2 times the upper limit of normal) that are clinically significant;\n12. Serious digestive disorders including severe gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), Crohn's disease, chronic constipation and\u002For diarrhea, etc.;\n13. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy;\n14. Current or history of eating disorders;\n15. Abnormal bleeding or coagulopathy (self-report) or history of a bleeding disorder or clotting abnormality;\n16. Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD);\n17. Dyslipidemia (fasting triglycerides \\>500 mg\u002FdL; low-density lipoprotein cholesterol (LDL-C) \\>190 mg\u002FdL);\n18. Whole blood donation in the last 3 months or platelet\u002Fplasma donation in the last week or plans for donation during entire protocol period;\n19. Receiving active treatment (including monoclonal antibodies) for autoimmune disorders within the last 6 months;\n20. Alcohol consumption \\>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month);\n21. Current smokers (smoking or use of any tobacco or e-cigarette\u002Fe-nicotine\u002FTHC\u002Fcannabis products in the last 3 months); stopped smoking \\\u003C10 years at time of screening for those with a \\>20 pack-year smoking history or stopped smoking \\\u003C5 years at time of screening for those with a \\\u003C20 pack-year smoking history;\n22. Night shift work in the last 6 months or planning night shift work during the study period;\n23. Known allergy to lidocaine or other local anesthetic;\n24. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting;\n25. Previous bariatric or other surgery for obesity;\n26. History of cancer (other than non-melanoma skin cancer) within the last 5 years (not in remission); anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months;\n27. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year;\n28. Currently pregnant (pregnancy test performed on day of DEXA scan in women of child-bearing potential); post-partum during the last 12 months; lactating during the last 12 months; planning to become pregnant during the participation period;\n29. Polycystic Ovarian Syndrome (PCOS) (self-report);\n30. Metabolic bone disease (self-report) including history of non-traumatic fracture from a standing height or less and\u002For current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen;\n31. Hospitalization for COVID-19 infection in the past 12 months; individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days;\n32. Partial and\u002For full hysterectomy (self-report);\n33. Not willing to archive biospecimens for future use;\n34. Not willing to undergo the microdialysis procedure;\n35. Participants who fulfill any of the contraindications for MRI including metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos;\n36. Unable to participate in MR assessments due to claustrophobia or physical limitations of equipment tolerances (e.g., MRI bore size) based on investigator's judgment at screening;\n37. Positive toxicology result from screening;\n38. The following medication use is exclusionary:\n\n    * Dose change for any chronic-use drug in the last 3 months;\n    * Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg\u002Fday);\n    * Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit\u002FHyperactivity Disorder (ADHD) drugs, anti-psychotic drugs;\n    * Pulmonary\u002FInflammation: chronic oral steroids (inhaled steroids are allowed), burst\u002Ftaper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months);\n    * Genitourinary: 5-alpha reductase inhibitors, daily phosphodiesterase type 5 inhibitor;\n    * Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and\u002For progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone, any drugs used to treat diabetes mellitus or lower blood glucose, metformin for any indication, any drugs used specifically to induce weight loss, any drugs used specifically to induce muscle growth\u002Fhypertrophy or augment exercise-induced muscle hypertrophy;\n    * Pain\u002FInflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week;\n    * Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous\u002Fchronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications\u002Fimmune suppressants;\n39. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.","45 Years",{"count":129,"type":20},70,[23],"The purpose of this research study is to study the effects of endurance exercise training on adipose (fat) tissue quality and insulin sensitivity in men and women.",[133],"Obesity","2026-03-24",{"date":136,"type":36},"2026-03-27",{"date":138,"type":36},"2024-09-11",{"date":140,"type":20},"2029-04",{"name":42,"class":43},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":70},"100625352","phase-2-ketone-monitoring-approaches-for-diabetic-ketoacidosis-risk-mitigation-in-people-with-t1d-on-adjunctive-sglt-2-inhibitors-100625352","NCT07421518","Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT2 Inhibitors","KARMA","Inclusion Criteria:\n\n1. Men and nonpregnant women ≥18 years and older\n2. Diagnosis of T1D according to American Diabetes Association (ADA) criteria\n3. HbA1c \\\u003C 9 %\n4. Participants treated with multiple daily injections of insulin, insulin pump, or advanced insulin delivery systems\n5. Has provided written informed consent to participate in the study.\n6. Must be willing to wear the investigational device\n7. Use of adequate contraception for the duration of the study by women of childbearing potential\n\nExclusion Criteria:\n\n1. Pregnancy, lactation or planning to become pregnant\n2. Any form of diabetes other than T1D\n3. People with T1D using weekly insulin (when approved)\n4. Use of sodium-glucose cotransporter 2 inhibitors within 4 weeks prior to screening\n5. Chronic systematic corticosteroids (\\>4 consecutive weeks) within 6 months before screening\n6. History of diabetic ketoacidosis within 6 months of screening\n7. History of multiple (≥ 3 infections) genital mycotic infections within 6 months of screening\n8. Hypotension at screening is defined as systolic blood pressure \\\u003C 90 and diastolic blood pressure \\\u003C 60 with symptoms of low blood pressure (confusion, dizziness, lightheadedness, fainting, heart palpitations)\n9. History of a level 3 hypoglycemic event (as defined by ADA criteria) within 3 months of screening\n10. Recent myocardial infarction, stroke, hospitalization for unstable angina or heart failure within 3 months prior to screening\n11. New York Heart Association Class IV heart failure\n12. CKD-EPI estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m²\n13. Impairment of systems and organs that may increase their risk of participating in the intervention study or compromise the results (for example: end stage kidney disease, active liver dysfunction, gastroparesis, anemia, ), organ transplant.\n14. Cancer treatment (excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer) within one year of screening\n15. Active Hepatitis B or C, acquired immunodeficiency syndrome (HIV infection controlled with suppressive medications is allowed) or tuberculosis\n16. Abnormal liver function at screening defined as any of the following: aspartate aminotransferase (AST) \\>2X upper limit of the normal reference range (ULN), ALT \\>2X ULN, serum total bilirubin (TB) \\>1.5X ULN\n17. Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites, or hepatic encephalopathy), and\u002For known diagnosis of cirrhosis\n18. Heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week) at screening, history of alcohol use disorder or binge drinking\n19. Any condition or factor that would compromise the participant's safety or the scientific integrity of the study (cognitive impairment, bipolar disorder, or history of eating disorder)\n20. Inability to perform the study follow up\u002F unwilling to wear the investigational device\n21. People who are unwilling to consume at least 20% of calories from carbohydrates","40 Years",{"count":153,"type":20},75,[155],"PHASE2","The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2 diabetes). This special education plan is compared to a general education plan and considers the higher risk of DKA when using medicines like SGLT2 inhibitors.",[158,59],"Type 1 Diabetes","2026-02-17",{"date":161,"type":36},"2026-02-19",{"date":90,"type":20},{"date":164,"type":20},"2030-04",{"name":42,"class":43},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100498660","adaptive-randomization-of-aerobic-exercise-during-chemotherapy-in-colon-cancer-100498660","NCT05773144","Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer","ACTION","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed stage II or III colon cancer\n* Completed surgical resection with curative intent\n* Plan to initiate chemotherapy\n* Engage in \\\u003C60 minutes per week of moderate- to vigorous-intensity structured aerobic exercise\n* No planned major surgery during the study period\n* Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire\n* Can walk 400 meters\n* Can read and speak English\n* Ability to provide written informed consent\n* Provide written approval by qualified healthcare professional\n* Willing to be randomized\n\nExclusion Criteria:\n\n* Evidence of metastatic colon cancer\n* Concurrently actively treated other (non-colon) cancer\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks\n* Currently participating in another study with competing outcomes\n* Any other condition that, in the opinion of the investigator, would preclude participation or successful compliance with the protocol\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",{"count":174,"type":20},219,[23],"To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.",[178],"Colonic Neoplasms","2026-01-05",{"date":181,"type":36},"2026-01-07",{"date":183,"type":36},"2023-06-01",{"date":185,"type":20},"2027-05-01",{"name":42,"class":43},3,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":70},"100499913","effects-of-aerobic-exercise-on-skeletal-muscle-remodeling-in-colorectal-cancer-100499913","NCT05789433","Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer","RESTORE","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed stage I, II, or III colon or rectal cancer\n* Completed surgical resection with curative intent\n* Completed other cancer-directed treatments\n* Engage in \\\u003C150 minutes per week of moderate- to vigorous-intensity structured endurance exercise\n* No planned major surgery during the study period\n* Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire\n* Ability to provide written informed consent\n* Provide written approval by a qualified healthcare professional\n* Willing to be randomized\n\nExclusion Criteria:\n\n* Evidence of metastatic or recurrent colorectal cancer\n* Concurrently actively treated other (non-colorectal) cancer\n* Scheduled to receive other postoperative cancer-directed treatment(s)\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks\n* Currently participating in another study with competing outcomes\n* Contraindications to magnetic resonance imaging\n* Any dietary condition or restriction that would limit tolerance of a mixed meal challenge\n* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",{"count":129,"type":20},[23],"The goal of this clinical trial is to quantify the effects of aerobic exercise training compared to attention control on intermuscular adipose tissue in colorectal cancer survivors.",[178,199],"Rectal Neoplasms","2025-07-01",{"date":202,"type":36},"2025-07-03",{"date":204,"type":36},"2023-05-01",{"date":206,"type":20},"2027-03-01",{"name":42,"class":43},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":217,"studyType":83,"phases":4,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":70},"100424512","adventhealth-research-institute-non-alcoholic-fatty-liver-disease-biobank-and-registry-avail-100424512","NCT04807868","AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)","AVAIL","Inclusion Criteria\n\n* Females and Males ≥ 18 years of age.\n* Understands the procedures and agrees to participate by giving written informed consent.\n\nBiopsy Group Only:\n\n• Scheduled for standard of care liver biopsy for any reason.\n\nNon-Biopsy Group Only:\n\n• BMI ≥ 25, with or without type 2 diabetes, without any level of NAFLD based on: (1) Recent medical history (within 6 months of screening visit). (2) Data collected from participation in a prior research study where they consented to be re-contacted for future studies.\n\nExclusion Criteria\n\n* Women who are pregnant when referred for a liver biopsy will be excluded.\n* Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.\n\nOtherwise, all eligible patients who consent will be included in AVAIL. If participants in the non-biopsy group are found to have NAFLD based on the FibroScan done for this study, then they will be informed of this and advised to follow up with their physician. Their data will still be part of the registry and analyzed with the biopsy group that is found to have NAFLD.",{"count":216,"type":20},1250,"5 Years","The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood\u002Furine samples, FibroScan and relevant data will also be collected.",[220],"Non-Alcoholic Fatty Liver Disease",[222],"NAFLD","2025-03-12",{"date":225,"type":36},"2025-03-13",{"date":227,"type":36},"2021-04-22",{"date":229,"type":20},"2026-03",{"name":42,"class":43},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":51,"sex":16,"minAge":238,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":70},"100344190","the-role-of-type-2-diabetes-on-skeletal-muscle-atrophy-and-recovery-following-bed-rest-in-older-adults-100344190","NCT03761446","The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults","REST","Inclusion Criteria\n\n1. Participant must be male or female between the ages of 60 and 80 years of age.\n2. Participant has pre-diabetes or type 2 diabetes and is only taking DPP-4 inhibitors, Sulfonylureas and\u002For Metformin therapy (but not Insulin, injectable incretin mimeticsSGL2 inhibitors, and Thiazolidinedione's), and has an A1C \\\u003C 8.0.\n\n   1. Pre-Diabetics are defined as having an HgbA1c of greater than or equal to 5.7% and less 6.5%, or a fasting glucose of greater than or equal to 100 mg\u002Fdl and less than 126 mg\u002Fdl or has a glucose of greater than or equal to 140 mg\u002Fdl and less than 200mg\u002Fdl at the 2 hour blood draw during OGTT\n   2. The non-diabetic control group is defined as having an HgbA1c of less than 5.7%, a fasting glucose of less than 100 mg\u002Fdl and a glucose level less than 140 mg\u002Fdl at the 2hr blood draw during the OGTT.\n3. Participant must have renal function with an estimated glomerular filtration rate (eGFR) \\> 45 ml\u002Fmin\u002F1.73m2 determined at screening.\n4. Participant's triglyceride level is \\\u003C 350 mg\u002Fdl and LDL cholesterol is ≤ 150 mg\u002Fdl at screening.\n5. Participants must be non-smokers. Non-smokers as defined by not smoking any tobacco or using nicotine-containing products and not using vape pens or vaporizers within 3 months prior to screening.\n6. Participant states willingness to follow protocol as described, including consumption of study product per protocol, the prescribed activity level and completing any forms needed throughout the study.\n7. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board\u002FIndependent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.\n\nExclusion Criteria\n\n1. Participant has type 1 Diabetes.\n2. BMI \\> 40.0 kg\u002Fm2\n3. Participant is actively pursuing weight loss and\u002For lifestyle changes.\n4. Participant has a history of pressure ulcers.\n5. Participant has a stated history of Deep Vein Thrombosis (DVT), pulmonary embolism, or a known hypercoagulable condition, or other clotting or bleeding disorders.\n6. History of gastrointestinal or intracranial hemorrhage.\n7. History of stroke or cerebrovascular accident.\n8. Recent history of major trauma (within 3 months).\n9. Thrombocytopenia (of any cause) or hyperkalemia (K \\> 5.0) on screening laboratory assay. May repeat lab value per PI discretion.\n10. Untreated or poorly controlled hypertension (SBP \\> 150, DBP \\> 95), or hypotension (SBP \\\u003C100 DBP \\\u003C60)\n11. Participant has a TSH greater than or equal to 10mIU\u002FL.\n12. Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.\n13. Participant is currently taking anti-inflammatory medication or has anti-inflammatory medication in the 1 weeks prior to screening (including over the counter formulations; e.g. Aleve, Motrin, ibuprofen, naproxen).\n14. Participant has had surgery requiring \\> 2 days of hospitalization in the last 1 month prior to screening visit.\n15. Participant has an active malignancy or autoimmune disease.\n16. Participant has current significantly impaired liver function in the opinion of the study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit.\n17. Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.\n18. Participant is an amputee and\u002For has presence of partial or full artificial limb.\n19. Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.\n20. Participant has a history of, or currently has uncontrolled severe diarrhea, nausea or vomiting.\n21. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.\n22. Participant cannot abstain from alcohol for the pre bed rest and bed rest portion of the study. For the recovery portion of the study the participant must agree to consume no more than 1 glass of wine (4-5 oz) or bottle of beer (12 oz) \u002Fday.\n23. Participant cannot refrain from taking medications\u002Fdietary supplements\u002Fherbals or substances that could modulate glucose metabolism (other than oral hypoglycemic medications), or are considered anabolic, or reduce weight (fat mass), or that may interact with low-molecular weight heparin or induce hypo- or hyper-coagulable state, in the opinion of the PI or medical provider, starting one week prior to enrollment and over the entire course of the study. These include progestational agents (except prescribed birth control), steroids, growth hormone, dronabinol, marijuana, calcium-beta-hydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and dietary supplements to aid weight loss.\n24. Participant has a mini-Mental State Examination score \\\u003C 21.\n25. Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos.\n26. Unable to participate in MR or DEXA assessments due to physical limitations of equipment tolerances (e.g., MRI bore size and DEXA 450-pound weight limit) claustrophobia, or based on Investigator's judgment at screening.\n27. Participant has a sensitivity or allergy to lidocaine.\n28. Participant has a sensitivity or allergy to heparin, enoxaparin, or other low molecular weight heparin.\n29. History of allergy to pork products or any component of the formulation of low-molecular weight heparin for dosing.\n30. History of heparin induced thrombocytopenia.\n31. Hemoglobin \\\u003C 10.0 g\u002FdL for females; \\\u003C 11.0 g\u002FdL for males; or participant has clinically significant signs\u002Fsymptoms of anemia in the opinion of the PI or medical provider.\n32. Concomitant medications with known contraindication or interaction with low-molecular weight heparin (including anti-platelet agents, anti-coagulant agents, non-steroidal anti-inflammatory drugs)\n33. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.\n34. Participant experiences symptoms of claudication. Symptoms include cramping pain in the legs and\u002For difficulty walking.","60 Years","80 Years",{"count":241,"type":20},50,[23],"The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.",[59,245,246,247,248],"Muscle Atrophy","Aging","Sedentary Behavior","Pre-diabetes",{"date":225,"type":36},{"date":251,"type":36},"2019-03-18",{"date":253,"type":20},"2025-12",{"name":42,"class":43},""]